BioNTech veröffentlicht Ergebnisse des ersten Quartals 2020 und Informationen zur Geschäftsentwicklung
May 12, 2020 08:05 ET
|
BioNTech SE
Globale Phase-1/2-Studie für BNT162-Impfstoffprogramm zur Prävention einer COVID-19-Infektion befindet sich in der Dosiseskalationsphase in Europa und den Vereinigten Staaten; in beiden Regionen wurde...
BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress
May 12, 2020 08:05 ET
|
BioNTech SE
Global Phase 1/2 clinical trial for BNT162 vaccine program to prevent COVID-19 infection in dose escalation phase in Europe and the U.S.; first cohorts dosed in both regionsBNT122 Phase 1/2 trial...
Translate Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 16:26 ET
|
Translate Bio, Inc.
-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...
Inhibitory Effect of Innovation Pharmaceuticals’ Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute
May 05, 2020 09:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has executed...
CENTOGENE Announces Global Expansion of COVID-19 Testing
May 05, 2020 09:30 ET
|
Centogene AG
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN,, May 05, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...
NSF Awards $200K Grant to Clarkson Professors Studying Transmission of SARS-CoV-2 Virus
April 28, 2020 16:34 ET
|
Clarkson University
Potsdam, NY, April 28, 2020 (GLOBE NEWSWIRE) -- Recent scientific and media reports have highlighted the risk of airborne transmission of the SARS-CoV-2 virus, which causes COVID-19. While it is...
Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4
April 27, 2020 09:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been...
JPT Launches Broad Spectrum of COVID-19 Peptide Tools for Immune Monitoring, Vaccine & Diagnostics Development
April 22, 2020 07:00 ET
|
JPT Peptide Technologies
BERLIN, April 22, 2020 (GLOBE NEWSWIRE) -- JPT Peptide Technologies (JPT) announces the launch of ready-to-use peptide tools to study and profile the immune response towards SARS-CoV-2 infection....
Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19
April 20, 2020 09:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that based on molecular...
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
April 15, 2020 08:00 ET
|
7 Hills Pharma
HOUSTON, April 15, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on development of drugs for the treatment and prevention of cancer and infectious diseases,...